AU2013218441A1 - Lupane triterpenoid derivatives and pharmaceutical use thereof - Google Patents

Lupane triterpenoid derivatives and pharmaceutical use thereof Download PDF

Info

Publication number
AU2013218441A1
AU2013218441A1 AU2013218441A AU2013218441A AU2013218441A1 AU 2013218441 A1 AU2013218441 A1 AU 2013218441A1 AU 2013218441 A AU2013218441 A AU 2013218441A AU 2013218441 A AU2013218441 A AU 2013218441A AU 2013218441 A1 AU2013218441 A1 AU 2013218441A1
Authority
AU
Australia
Prior art keywords
compound
independently
mmol
optionally substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013218441A
Other languages
English (en)
Inventor
Feng Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FENG Qiaodi
JIANGXI QINGFENG PHARMACEUTICAL Inc
Original Assignee
FENG QIAODI
JIANGXI QINGFENG PHARMACEUTICAL Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FENG QIAODI, JIANGXI QINGFENG PHARMACEUTICAL Inc filed Critical FENG QIAODI
Publication of AU2013218441A1 publication Critical patent/AU2013218441A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013218441A 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof Abandoned AU2013218441A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201210027090 2012-02-08
CN201210027090.4 2012-02-08
CN201310014849.XA CN103242413B (zh) 2012-02-08 2013-01-15 Lupane三萜系衍生物及其药学用途
CN201310014849X 2013-01-15
PCT/CN2013/071100 WO2013117137A1 (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
AU2013218441A1 true AU2013218441A1 (en) 2014-07-24

Family

ID=48922317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013218441A Abandoned AU2013218441A1 (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof

Country Status (12)

Country Link
US (1) US9428542B2 ( )
EP (1) EP2812343B1 ( )
JP (1) JP5872074B2 ( )
KR (1) KR20140126739A ( )
CN (1) CN103242413B ( )
AU (1) AU2013218441A1 ( )
BR (1) BR112014018953A8 ( )
CA (1) CA2860581A1 ( )
EA (1) EA201491479A1 ( )
HK (1) HK1202553A1 ( )
WO (1) WO2013117137A1 ( )
ZA (1) ZA201405819B ( )

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
EP3218387A1 (en) * 2014-11-14 2017-09-20 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
WO2016077572A1 (en) * 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Extended betulinic acid analogs
EP3218388A1 (en) * 2014-11-14 2017-09-20 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
WO2018029602A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-28 heterocycle derivatives as hiv inhibitors
WO2018029604A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
WO2018029610A1 (en) * 2016-08-09 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 n-amide derivatives as hiv inhibitors
WO2018065930A1 (en) * 2016-10-05 2018-04-12 Hetero Labs Limited C-3 triterpenone with c-17 reverse amide derivatives as hiv inhibitors
WO2018069857A1 (en) * 2016-10-12 2018-04-19 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide heterocycle derivatives as hiv inhibitors
WO2019150300A1 (en) 2018-02-02 2019-08-08 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
CN114369134A (zh) * 2020-10-15 2022-04-19 江西青峰药业有限公司 一种Lupane三萜系衍生物葡甲胺盐无定型物及其制备方法和应用
CN115504947B (zh) * 2022-08-23 2024-04-26 山东和源制药有限公司 一种呋喃酮酸的制备方法
CN116041415B (zh) * 2023-02-01 2023-08-18 吉林农业大学 一种裂环羽扇豆烷衍生物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
AR063546A1 (es) * 2006-11-03 2009-01-28 Panacos Pharmaceuticals Inc DERIVADOS DE TRITERPENO, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIoN POR EL VIRUS VIH.
WO2009073818A1 (en) * 2007-12-04 2009-06-11 Myriad Genetics, Inc. Compounds and therapeutic use thereof
JP2011508748A (ja) * 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のルパン誘導体
CN101977924A (zh) * 2008-01-03 2011-02-16 Viro化学制药公司 新的c-21-酮基羽扇烷衍生物、其制备方法和应用
JP2013519674A (ja) 2010-02-11 2013-05-30 グラクソスミスクライン エルエルシー ベツリンの誘導体
JO3387B1 (ar) * 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين

Also Published As

Publication number Publication date
US9428542B2 (en) 2016-08-30
HK1202553A1 (en) 2015-10-02
CA2860581A1 (en) 2013-08-15
JP2015505545A (ja) 2015-02-23
KR20140126739A (ko) 2014-10-31
WO2013117137A1 (en) 2013-08-15
CN103242413B (zh) 2015-08-26
EA201491479A1 (ru) 2014-11-28
EP2812343B1 (en) 2019-03-13
ZA201405819B (en) 2015-12-23
JP5872074B2 (ja) 2016-03-01
BR112014018953A8 (pt) 2017-07-11
CN103242413A (zh) 2013-08-14
EP2812343A1 (en) 2014-12-17
US20150011517A1 (en) 2015-01-08
BR112014018953A2 ( ) 2017-06-20
EP2812343A4 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
AU2013218441A1 (en) Lupane triterpenoid derivatives and pharmaceutical use thereof
ES2972512T3 (es) Compuestos de aminoácido y métodos de uso
CA3137025A1 (en) Bicyclic compounds
ES2672530T3 (es) Amidas heterocíclicas como inhibidores de cinasas
CA3073543A1 (en) Benzosulfonyl compounds
ES2542425T3 (es) Pirrolo[1,2-b]pirazol piridinoquinoleino substituido monohidrato como inhibidor del TBF-beta
CA2963973C (en) Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
ES2730942T3 (es) Derivados de triazolopiridina como moduladores de la actividad de TNF
BRPI0923670A2 (pt) inibidores da atividade de proteÍna tirosina quinase e seu uso, bem como composiÇço compreendendo os mesmos
BRPI0716641A2 (pt) Moduladores de receptor de glicocorticóide, e/ou ap-1, e/ou atividade de nf-kb e uso destes
RU2656209C2 (ru) Терапевтически активные производные оксазолина
AU2019272538B2 (en) Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
CN112851663B (zh) 一种并杂环化合物及其用途
CN112707905B (zh) 一种三并杂环化合物及其制备方法和用途
WO2022087008A1 (en) Tertiary carboxamide compounds
CA3218442A1 (en) Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
CA2951419A1 (en) Pyrazolo-pyridine derivatives as kinase inhibitors
CN118234733A (zh) 一类五元杂环并嘧啶类衍生物及其作为泛kras突变抑制剂的用途
CA3063804A1 (en) A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof
AU2021218739A1 (en) Inhibitors of ULK1/2 and methods of using same
JP2023513793A (ja) 大環状ｕｌｋ１／２阻害剤
WO2017143011A1 (en) Histone demethylase inhibitors
AU2005295016A1 (en) 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives
CN113966331B (zh) 含脲结构的三芳环化合物及其应用
CA2702990A1 (en) Compounds for inhibiting ksp kinesin activity

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period